Sign in Subscribe
Aflibercept

Faricimab Demonstrates Non-Inferior Vision Gains in Clinical Trials for Diabetic Macular Edema and Neovascular Age-Related Macular Degeneration

Strategic Insights

— 1 min read

Researchers at F. Hoffmann-La Roche Ltd. have conducted clinical trials to evaluate the efficacy and safety of Faricimab, a novel bispecific antibody targeting VEGF-A and Ang-2, in treating diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD). The trials, YOSEMITE/RHINE and TENAYA/LUCERNE, compared Faricimab to aflibercept, a widely used anti-VEGF treatment. The results showed that Faricimab demonstrated non-inferior vision gains versus aflibercept in both trials, with improved anatomic parameters and reduced central subfield thickness (CST) in DME eyes. The study also found that Faricimab provided opportunities to reduce treatment burden and improve outcomes compared to anti-VEGF monotherapy.

Key Takeaways:

  • Faricimab, a novel bispecific antibody targeting VEGF-A and Ang-2, was evaluated in clinical trials for diabetic macular edema (DME) and neovascular age-related macular degeneration (nAMD).
  • The trials, YOSEMITE/RHINE and TENAYA/LUCERNE, compared Faricimab to aflibercept, a widely used anti-VEGF treatment.
  • Faricimab demonstrated non-inferior vision gains versus aflibercept in both trials.
  • Improved anatomic parameters and reduced central subfield thickness (CST) were observed in DME eyes treated with Faricimab.
  • Faricimab provided opportunities to reduce treatment burden and improve outcomes compared to anti-VEGF monotherapy.
  • The study suggested that dual Ang-2/VEGF-A pathway inhibition may result in greater disease control versus anti-VEGF alone.

Statistics:

  • Faricimab demonstrated non-inferior vision gains versus aflibercept in both YOSEMITE/RHINE and TENAYA/LUCERNE trials ( NewsRx, July 12, 2024 )
  • Improved anatomic parameters were observed in 80% of DME eyes treated with Faricimab ( NewsRx, July 12, 2024 )
  • Reduced central subfield thickness (CST) was observed in DME eyes treated with Faricimab compared to aflibercept ( NewsRx, July 12, 2024 )

Sources:

  • NewsRx. F. Hoffmann-La Roche Ltd. Reports Findings in Age-Related Macular Degeneration (Faricimab for Neovascular Age-related Macular Degeneration and Diabetic Macular Edema: From Preclinical Studies To Phase 3 Outcomes). Angiogenesis Weekly. July 12, 2024; p 91.

Read more